Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab with enfortumab vedotin within its marketing authorisation for treating untreated locally advanced or metastatic urothelial cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6332

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
27 February 2024 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early August 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
12 January 2024 - 09 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6332
12 January 2024 - 09 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6332
12 January 2024 In progress. Scoping commencing
16 December 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
16 December 2022 Topic selection

For further information on our processes and methods, please see our CHTE processes and methods manual